Ignite Proteomics Company Profile

Background

Ignite Proteomics LLC, a subsidiary of IMAC Holdings, Inc. (Nasdaq: BACK), specializes in advanced proteomic diagnostics to enhance precision oncology. Established in 2024, the company focuses on developing assays that measure functional protein activity within tumors, providing oncologists with critical insights for personalized cancer treatment. By leveraging Reverse Phase Protein Array (RPPA) technology, Ignite Proteomics aims to bridge the gap left by traditional genomic tests, offering a more comprehensive understanding of tumor behavior and drug response.

Key Strategic Focus

Ignite Proteomics is dedicated to advancing precision oncology through the development and commercialization of proteomic assays that assess both the expression and activation levels of key proteins in cancer cells. Their primary objective is to provide actionable data that enables oncologists to tailor treatments more effectively, particularly in breast cancer cases. The company's core specialization lies in utilizing RPPA technology to analyze protein activity, thereby identifying potential therapeutic targets and predicting patient responses to specific treatments. This approach targets the growing need for personalized medicine in oncology, addressing the limitations of genomic testing by focusing on real-time protein function.

Financials and Funding

As a subsidiary of IMAC Holdings, Inc., Ignite Proteomics benefits from the financial backing and strategic support of its parent company. IMAC Holdings has initiated a rebranding process to operate as IMAC Holdings, Inc., DBA Ignite Sciences, Inc., reflecting a consolidated focus on innovative healthcare solutions. Specific funding details for Ignite Proteomics are not publicly disclosed; however, the integration of proprietary laboratory capabilities and intellectual property, such as the acquisition of PLA code 0249U, indicates a strategic investment in the company's growth and development.

Pipeline Development

Ignite Proteomics' flagship product is its advanced proteomic assay for breast cancer diagnostics. This assay measures functional protein activity in breast tumors, providing insights into how patients might respond to targeted therapies. The assay has been clinically validated and is conducted in a CLIA-certified, CAP-accredited, and New York State–approved laboratory, ensuring high-quality standards. The company is actively collaborating with leading cancer centers to expand clinical evidence and incorporate its test into routine care, aiming to establish the assay as a standard component in breast cancer treatment guidelines.

Technological Platform and Innovation

Ignite Proteomics distinguishes itself through its proprietary use of Reverse Phase Protein Array (RPPA) technology, a high-throughput method that allows for the quantitative analysis of protein expression and activation in tumor samples. This technology enables the simultaneous measurement of multiple protein biomarkers, providing a comprehensive profile of tumor biology. Key innovations include:

Proprietary Technologies: The company's proteomic assay is protected by licensed patents covering several novel biomarkers, ensuring a unique platform for guiding advanced treatment choices.

Significant Scientific Methods: Utilizing RPPA technology, Ignite Proteomics can assess the phosphorylation (activation) status of proteins within critical signaling pathways, such as the AKT–mTOR pathway, which plays a pivotal role in cell growth and survival.

Leadership Team

The leadership team at Ignite Proteomics comprises experienced professionals dedicated to advancing precision oncology:

Faith Zaslavsky: Serving as the Chief Executive Officer of both IMAC Holdings and Ignite Proteomics, Ms. Zaslavsky brings extensive experience in healthcare management and strategic development.

Justin Davis, PhD: As the Vice President of Research and Development, Dr. Davis oversees the scientific and technological advancements of the company's proteomic assays.

Leadership Changes

In January 2025, IMAC Holdings announced the launch of Ignite Proteomics, appointing Faith Zaslavsky as CEO to lead the new subsidiary. This strategic move reflects the company's commitment to expanding its presence in precision oncology diagnostics.

Competitor Profile

Market Insights and Dynamics

The precision oncology diagnostics market is experiencing significant growth, driven by the increasing demand for personalized cancer treatments. Traditional genomic testing has been the cornerstone of this market; however, the limitations of genomics in predicting treatment response have led to a growing interest in proteomic approaches. The global precision oncology market is projected to reach $99.7 billion by 2030, with a compound annual growth rate (CAGR) of 9.8%.

Competitor Analysis

Key competitors in the proteomic diagnostics space include:

Theralink Technologies, Inc.: Prior to Ignite Proteomics' acquisition of PLA code 0249U, Theralink was a notable player in the proteomic assay market. The transfer of this code signifies Ignite's strategic positioning in the field.

Perthera: Collaborated on studies highlighting the importance of protein activation measurement in cancer treatment selection, indicating a focus on personalized oncology solutions.

The competitive landscape is characterized by a shift towards integrating proteomic data with genomic information to enhance treatment decision-making, positioning companies like Ignite Proteomics at the forefront of this evolution.

Strategic Collaborations and Partnerships

Ignite Proteomics actively collaborates with leading cancer centers to expand clinical evidence and incorporate its proteomic assay into routine care. These partnerships aim to validate the clinical utility of the assay and facilitate its adoption as a standard component in breast cancer treatment guidelines.

Operational Insights

Strategically, Ignite Proteomics differentiates itself by focusing on protein-level analysis, addressing the limitations of genomic testing in predicting treatment responses. The acquisition of PLA code 0249U and the establishment of a dedicated reimbursement pathway enhance the company's market position and facilitate broader adoption of its assay. Operating under a CLIA-certified, CAP-accredited, and New York State–approved laboratory ensures compliance with stringent quality standards, further strengthening its competitive advantage.

Strategic Opportunities and Future Directions

Looking ahead, Ignite Proteomics plans to:

Expand Clinical Applications: Broaden the use of its proteomic assay beyond breast cancer to other tumor types, leveraging the versatility of RPPA technology.

Enhance Technological Capabilities: Invest in research and development to refine assay sensitivity and specificity, incorporating emerging biomarkers and analytical methods.

Strengthen Market Presence: Pursue strategic partnerships and collaborations to increase market penetration and establish the assay as a standard tool in precision oncology.

By capitalizing on its current strengths and addressing unmet needs in cancer diagnostics, Ignite Proteomics is well-positioned to contribute significantly to the advancement of personalized medicine.